Ontario Institute for Cancer Research Statement of Revenue and Expenses and Changes in Net Assets

Year ended March 31, 2020

	Cancer Research Program	External Grants Program	Total 2020	Total 2019
Revenue				
Government of Ontario funding Other grants Rent Fees, workshops and other income	\$ 73,381,753 4,330,397 1,436,319 318,310 79,466,779	\$ - 10,678,920 - - - 10,678,920	\$ 73,381,753 15,009,317 1,436,319 318,310 90,145,699	\$ 73,891,283 17,655,701 1,402,823 199,896 93,149,703
Equity (loss) income in Fight Against Cancer Innovation Trust	(4,839,045)	-	(4,839,045)	1,768,787
Total Revenue	\$ 74,627,734	\$ 10,678,920	\$ 85,306,654	\$ 94,918,490
Expenses Investigator and research Salaries and benefits Amortization Rent, utilities, taxes and building maintenance Office and general Contracted services Information system Workshops and conferences Marketing and communications Professional fees	\$ 34,415,167 25,078,077 3,792,388 8,643,871 3,161,919 409,297 895,528 151,276 63,447 215,206	\$ 2,902,393 6,021,978 1,819 - 456,041 828,292 293,673 157,215 17,509	\$ 37,317,560 31,100,055 3,794,207 8,643,871 3,617,960 1,237,589 1,189,201 308,491 80,956 215,206	\$ 39,566,929 31,289,350 4,449,877 8,560,004 3,476,849 1,561,155 1,205,935 458,209 199,556 212,884
Total Expenses	\$ 76,826,176	\$ 10,678,920	\$ 87,505,096	\$ 90,980,748
(Deficiency) excess of revenue over expenses for the year Transactions directly impacting FACIT equity	(2,198,442) (141,300)	-	(2,198,442) (141,300)	3,937,742 19,812,526
Net assets, beginning of the year	51,354,796	-	51,354,796	27,604,528
Net assets, end of the year	\$ 49,015,054		\$ 49,015,054	\$ 51,354,796

Management statements. The audited financial statements for the 2019-20 fiscal year are available upon request.

Ontario Institute for Cancer Research Statement of Financial Position

March 31, 2020

	2020	2019
Assets		
Current		
Cash	\$ 22,218,573	\$ 18,508,822
Accounts receivable	4,958,153	6,754,481
Supplies	1,287,773	1,413,474
Prepaid expenses	2,153,443	2,128,504
	30,617,942	28,805,281
Long-term portion of prepaid expenses	729,109	1,080,873
Capital assets, net	13,979,940	15,167,711
Fight Against Cancer Innovation Trust	44,021,133	47,682,523
	\$ 89,348,124	\$ 92,736,388
Liabilities Current		
Accounts payable and accrued liabilities	\$ 7,994,928	\$ 10,355,869
Unearned rental revenue	570,311	564,179
	8,565,239	10,920,048
Deferred contributions	17,787,891	15,293,833
Deferred capital contributions	13,979,940	15,167,711
	\$ 40,333,070	\$ 41,381,592
Net assets	\$ 49,015,054	\$ 51,354,796
	\$ 89,348,124	\$ 92,736,388

Management statements. The audited financial statements for the 2019-20 fiscal year are available upon request.

Ontario Institute for Cancer Research Notes to the Financial Statements

March 31, 2020

	2020	2019
OPERATING ACTIVITIES		
(Deficiency) excess of revenue over expenses for the year	\$ (2,198,443)	\$ 3,937,742
Add (deduct) items not involving cash	,	
Amortization of capital assets	3,794,207	4,449,876
Amortization of deferred capital contribution	(3,794,207)	(4,449,876)
Equity loss (income) in Fight Against Cancer Innovation Trust	4,839,045	(1,881,455)
	2,640,602	2,056,287
Changes in non-cash balances related to operations		
Accounts receivable	1,796,328	(994,980)
Supplies	125,701	(270,084)
Prepaid expenses	326,826	(1,054,693)
Accounts payable and accrued liabilities	(2,360,941)	4,417,482
Unearned rental revenue	6,132	(1,097)
Deferred contributions	5,100,494	1,482,612
Cash provided from operating activities	\$ 7,635,142	\$ 5,635,527
INVESTING ACTIVITIES		
Purchase of capital assets, net	(2,606,436)	(2,359,501)
Capital Contribution to FACIT Dividend Received	(9,318,955) 8,000,000	(3,490,600)
Cash used in investing activities	\$ (3,925,391)	\$ (5,850,101)
Net change in cash during the year	3,709,751	(214,574)
Cash, beginning of year	18,508,822	18,723,396
Cash, end of year	\$ 22,218,573	\$ 18,508,822

Management statements. The audited financial statements for the 2019-20 fiscal year are available upon request.